Theron A Russell1, Melanie J Grubisha2, Christine L Remmers1, Seok Kyu Kang1, Marc P Forrest1, Katharine R Smith1, Katherine J Kopeikina1, Ruoqi Gao1, Robert A Sweet3, Peter Penzes4. 1. Department of Physiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois. 2. Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 3. Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania; VISN 4 Mental Illness Research, Education and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania. 4. Department of Physiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Department of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois. Electronic address: p-penzes@northwestern.edu.
Abstract
BACKGROUND: Large-scale genetic studies have revealed that rare sequence variants, including single nucleotide variants (SNVs), in glutamatergic synaptic genes are enriched in schizophrenia patients. However, the majority are too rare to show any association with disease and have not been examined functionally. One such SNV, KALRN-P2255T, displays a penetrance that greatly exceeds that of previously identified schizophrenia-associated SNVs. Therefore, we sought to characterize its effects on the function of kalirin (Kal)-9, a dual Ras-related C3 botulinum toxin substrate 1 and Ras homologue gene family, member A (RhoA) guanine nucleotide exchange factor, upregulated in human schizophrenia brain tissue. METHODS: Kal9 was overexpressed in primary rat cortical neurons or human embryonic kidney 293 (HEK293) cells. The effects of the P2255T variant on dendritic branching, dendritic spine morphology, protein and messenger RNA stability, and catalytic activity were examined. RESULTS: Kal9-P2255T leads to diminished basal dendritic branching and dendritic spine size, compared with wild-type Kal9. The P2255T SNV directly affected Kal9 protein function, causing increased RhoA activation in HEK293 cells, but had no effect on Ras-related C3 botulinum toxin substrate 1 activation. Consistent with human postmortem findings, we found that Kal9-P2255T protein levels were higher than those of wild-type Kal9 in neurons. Increased messenger RNA stability was detected in HEK293 cells, indicating that this was the cause of the higher protein levels. When analyzed together, increased intrinsic RhoA guanine nucleotide exchange factor catalytic activity combined with increased messenger RNA expression led to net enhancement of RhoA activation, known to negatively impact neuronal morphology. CONCLUSIONS: Taken together, our data reveal a novel mechanism for disease-associated SNVs and provide a platform for modeling morphological changes in mental disorders.
BACKGROUND: Large-scale genetic studies have revealed that rare sequence variants, including single nucleotide variants (SNVs), in glutamatergic synaptic genes are enriched in schizophreniapatients. However, the majority are too rare to show any association with disease and have not been examined functionally. One such SNV, KALRN-P2255T, displays a penetrance that greatly exceeds that of previously identified schizophrenia-associated SNVs. Therefore, we sought to characterize its effects on the function of kalirin (Kal)-9, a dual Ras-related C3 botulinum toxin substrate 1 and Ras homologue gene family, member A (RhoA) guanine nucleotide exchange factor, upregulated in humanschizophrenia brain tissue. METHODS: Kal9 was overexpressed in primary rat cortical neurons or humanembryonic kidney 293 (HEK293) cells. The effects of the P2255T variant on dendritic branching, dendritic spine morphology, protein and messenger RNA stability, and catalytic activity were examined. RESULTS: Kal9-P2255T leads to diminished basal dendritic branching and dendritic spine size, compared with wild-type Kal9. The P2255T SNV directly affected Kal9 protein function, causing increased RhoA activation in HEK293 cells, but had no effect on Ras-related C3 botulinum toxin substrate 1 activation. Consistent with human postmortem findings, we found that Kal9-P2255T protein levels were higher than those of wild-type Kal9 in neurons. Increased messenger RNA stability was detected in HEK293 cells, indicating that this was the cause of the higher protein levels. When analyzed together, increased intrinsic RhoA guanine nucleotide exchange factor catalytic activity combined with increased messenger RNA expression led to net enhancement of RhoA activation, known to negatively impact neuronal morphology. CONCLUSIONS: Taken together, our data reveal a novel mechanism for disease-associated SNVs and provide a platform for modeling morphological changes in mental disorders.
Authors: Jennifer Gladys Mulle; Anne F Dodd; John A McGrath; Paula S Wolyniec; Adele A Mitchell; Amol C Shetty; Nara L Sobreira; David Valle; M Katharine Rudd; Glen Satten; David J Cutler; Ann E Pulver; Stephen T Warren Journal: Am J Hum Genet Date: 2010-08-13 Impact factor: 11.025
Authors: Zachary P Wills; Caleigh Mandel-Brehm; Alan R Mardinly; Alejandra E McCord; Roman J Giger; Michael E Greenberg Journal: Neuron Date: 2012-02-09 Impact factor: 17.173
Authors: Nathan G Hedrick; Stephen C Harward; Charles E Hall; Hideji Murakoshi; James O McNamara; Ryohei Yasuda Journal: Nature Date: 2016-09-28 Impact factor: 49.962
Authors: Kevin M Woolfrey; Deepak P Srivastava; Huzefa Photowala; Megumi Yamashita; Maria V Barbolina; Michael E Cahill; Zhong Xie; Kelly A Jones; Lawrence A Quilliam; Murali Prakriya; Peter Penzes Journal: Nat Neurosci Date: 2009-09-06 Impact factor: 24.884
Authors: Euan Parnell; Lauren P Shapiro; Roos A Voorn; Marc P Forrest; Hiba A Jalloul; Daniel D Loizzo; Peter Penzes Journal: Gene Date: 2020-11-13 Impact factor: 3.688
Authors: Arne W Mould; Noura Al-Juffali; Annette von Delft; Paul E Brennan; Elizabeth M Tunbridge Journal: CNS Drugs Date: 2021-12-20 Impact factor: 5.749